Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer

Biomaterials

Volumn 55, Issue , 2015, Pages 54-63

  Vong, Long Binh ^a   Yoshitomi, Toru ^a,b   Matsui, Hirofumi ^a   Nagasaki, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Drug delivery system; Oral therapeutics; Redox nanoparticles; ROS

Indexed keywords

BIOCHEMISTRY; CHEMOTHERAPY; HISTOLOGY; NANOPARTICLES; TISSUE; TUMORS;

CANCER; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT; ORAL ADMINISTRATION; ORAL THERAPEUTICS; REACTIVE OXYGEN SPECIES; ROS; THERAPEUTIC EFFICACY;

DISEASES;

ANTINEOPLASTIC AGENT; AZOXYMETHANE; DEXTRAN SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; NANOPARTICLE; NITROXIDE; REACTIVE OXYGEN METABOLITE; REDOX NANOPARTICLE; UNCLASSIFIED DRUG; CAMPTOTHECIN; DEXTRAN; NITROGEN OXIDE; NITROXYL; SCAVENGER; SODIUM SULFATE; SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CANCER TISSUE; CLINICAL EFFECTIVENESS; COLITIS; COLITIS ASSOCIATED COLON CANCER; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; COLONIC NEOPLASMS; COMPLICATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; ENDOSCOPY; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; NANOMEDICINE; NEOPLASMS, EXPERIMENTAL; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CAMPTOTHECIN; CELL LINE, TUMOR; COLITIS; COLONIC NEOPLASMS; DEXTRANS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOSCOPY; FREE RADICAL SCAVENGERS; INFLAMMATION; MALE; MICE; MICE, INBRED ICR; NANOMEDICINE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; NITROGEN OXIDES; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SULFATES;

EID: 84929634545     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.037     Document Type: Article

References (51)

1. Abraham C., Cho J.H. Inflammatory bowel disease. NEngl J Med 2009, 361:2066-2078.
2. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
3. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
4. Podolsky D.K. Inflammatory bowel disease. NEngl J Med 2002, 347:417-429.
5. Grivennikov S.I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013, 35:229-244.
6. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009, 10:353-358.
7. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
8. Gommeaux J., Cano C., Garcia S., Gironella M., Pietri S., Culcasi M., et al. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol 2007, 27:2215-2228.
9. Cui X., Jin Y., Hofseth A.B., Pena E., Habiger J., Chumanevich A., et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 2010, 3:549-559.
10. Seril D.N., Liao J., Ho K.L., Yang C.S., Yang G.Y. Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 2002, 23:993-1001.
11. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
12. Mathijssen R.H., Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7:2182-2194.
13. Chen S., Yueh M.F., Bigo C., Barbier O., Wang K., Karin M., et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A 2013, 110:19143-19148.
14. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
15. Hrkach J., Hoff D.V., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128-139.
16. Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanomedicine. NEngl J Med 2010, 363:2434-2443.
17. Bisht S., Feldmann G., Koorstra J.B., Mullendore M., Alvarez H., Karikari C., et al. Invivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008, 7:3878-3888.
18. Ma L., Kohli M., Smith A. Nanoparticles for combination drug therapy. ACS Nano 2013, 7:9518-9525.
19. Bergin I.L., Witzmann F.A. Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int J Biomed Nanosci Nanotechnol 2013, 3:163-210.
20. Park E.J., Bae E., Yi J., Kim Y., Choi K., Lee S.H., et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ Toxicol Pharmacol 2010, 30:162-168.
21. Vong L.B., Tomita T., Yoshitomi T., Matsui H., Nagasaki Y. An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 2012, 143:1027-1036.
22. Sha S., Vong L.B., Chonpathompikunlert P., Yoshitomi T., Matsui H., Nagasaki Y. Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles. Biomaterials 2013, 34:8393-8400.
23. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
24. Vong L.B., Yoshitomi T., Morikawa K., Saito S., Matsui H., Nagasaki Y. Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis. JGastroenterol 2014, 49:806-813.
25. Yoshitomi T., Hirayama A., Nagasaki Y. The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles. Biomaterials 2011, 32:8021-8028.
26. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
27. Becker C., Fantini M.C., Neurath M.F. High resolution colonoscopy in live mice. Nat Protoc 2006, 1:2900-2904.
28. Lima-Junior R.C., Freitas H.C., Wong D.V., Wanderley C.W., Nunes L.G., Leite L.L., et al. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice. Br J Pharmacol 2014, 171:2335-2350.
29. Kurita A., Kado S., Kaneda N., Onoue M., Hashimoto S., Yokokura T. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother Pharmacol 2003, 52:349-360.
30. Johansson M.E., Sjovall H., Hansson G.C. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013, 10:352-361.
31. Morin P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65(21):9603-9606.
32. Yoshitomi T., Ozaki Y., Thangavel S., Nagasaki Y. Redox nanoparticle therapeutics to cancer-increase in therapeutic effect of doxorubicin, suppressing its adverse effect. JControl Release 2013, 172:137-143.
33. Xu Y., Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002, 13:1841-1851.
34. Kokura S., Yoshida N., Sakamoto N., Ishikawa T., Takagi T., Higashihara H., et al. The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB. Cancer Lett 2005, 229(2):223-233.
35. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-417.
36. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. JClin Invest 2001, 107:241-246.
37. Terzic T., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.
38. Kopec J.A., Yothers G., Ganz P.A., Land S.R., Cecchini R.S., Wieand H.S., et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. JClin Oncol 2007, 25:424-430.
39. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. JClin Oncol 2008, 26:2311-2319.
40. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004, 350:2335-2342.
41. Sargent D., Sobrero A., Grothey A., O'Connell M.J., Buyse M., Andre T., et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. JClin Oncol 2009, 27:872-877.
42. Dobbelstein M., Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 2014, 13:179-196.
43. Mitchell J.B., Anver M.R., Sowers A.L., Rosenberg P.S., Figueroa M., Thetford A., et al. The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation. Cancer Res 2012, 72:4846-4855.
44. Nagasaki Y. Nitroxide radicals and nanoparticles: a partnership for nanomedicine radical delivery. Ther Deliv 2012, 3:165-179.
45. Soule B.P., Hyodo F., Matsumoto K., Simone N.L., Cook J.A., Krishna M.C., et al. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007, 42:1632-1650.
46. Yoshitomi T., Miyamoto D., Nagasaki Y. Design of core-shell-type nanoparticles carrying stable radicals in the core. Biomacromolecules 2009, 10:596-601.
47. Chonpathompikunlert P., Fan C.H., Ozaki Y., Yoshitomi T., Yeh C.K., Nagasaki Y. Redox nanoparticle treatment protects against neurological deficit in focused ultrasound-induced intracerebral hemorrhage. Nanomedicine 2012, 7:1029-1043.
48. Marushima A., Suzuki K., Nagasaki Y., Yoshitomi T., Toh K., Tsurushima H., et al. Newly synthesized radical-containing nanoparticles enhance neuroprotection after cerebral ischemia-reperfusion injury. Neurosurgery 2011, 68:1418-1425.
49. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2009, 236:16-24.
50. Zhao J., Castranova V. Toxicology of nanomaterials used in nanomedicine. JToxicol Environ Health B Crit Rev 2011, 14:593-632.
51. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723.